Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Operating Expenses (2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Operating Expenses for 1 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a N/A change, with the full-year FY2020 number at -$1.1 million, changed N/A from a year prior.
  • Other Operating Expenses was $1.2 million for Q4 2025 at Neuphoria Therapeutics, up from $130381.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.2 million in Q4 2025 to a low of $130381.0 in Q1 2025.